新诊断多发性骨髓瘤患者个体化加权骨髓瘤预后评分系统(MPSS)的建立与验证
这项回顾性多队列研究收集了1792例新诊断多发性骨髓瘤(NDMM)患者的临床和遗传学数据,构建并验证了加权骨髓瘤预后评分系统(MPSS)以预测总生存期(OS)。MPSS将患者分为四组,中位OS分别为91.0、69.8、45.0和28.0个月(p < .001),并在内部和外部验证队列中保持预后价值。
要点
- MPSS基于血小板减少(2分)、乳酸脱氢酶升高(1分)、ISS III期(2分)、1个高危细胞遗传学异常(1分)和≥2个高危细胞遗传学异常(2分)构建。
- MPSS I至IV组的中位OS分别为91.0、69.8、45.0和28.0个月(p < .001)。
- MPSS在内部验证队列和独立外部验证队列中均保持预后价值,并与常规预后模型(R-ISS、R2-ISS和MASS)相比显示出显著的风险分布。
核心结论
- MPSS风险模型可预测NDMM患者的总生存期,并在内部和外部验证队列中保持预后价值。
- 在临床实践中使用MPSS模型可能改善NDMM患者的风险估计,从而促进个体化治疗策略。
研究设计与样本
- 回顾性、多队列研究,收集1792例新诊断多发性骨髓瘤(NDMM)患者的临床和遗传学数据。
- 使用排名靠前的预测特征构建加权骨髓瘤预后评分系统(MPSS)风险模型,并在训练队列、内部验证队列和独立外部验证队列中验证其预测总生存期(OS)的能力。
主要发现
- 在训练队列中,乳酸脱氢酶(LDH)升高、国际分期系统(ISS)III期、血小板减少和累积高危细胞遗传学异常(HRA)数目具有独立预后意义。
- 根据OS的风险比定义各风险因素的加权值:血小板减少2分、LDH升高1分、ISS III期2分、1个HRA 1分、≥2个HRA 2分。
- 患者被分为四组:MPSS I(22.5%,0分)、II(17.6%,1分)、III(38.6%,2-3分)和IV(21.3%,4-7分)。
- MPSS I至IV组的中位OS分别为91.0、69.8、45.0和28.0个月(p < .001)。
- MPSS模型在内部验证队列和独立外部验证队列中保持预后价值,并与常规预后模型(R-ISS、R2-ISS和MASS)相比显示出显著的风险分布。
关键数值与推荐
- MPSS评分:血小板减少2分、LDH升高1分、ISS III期2分、1个HRA 1分、≥2个HRA 2分。
- 风险分组:MPSS I(0分,22.5%)、II(1分,17.6%)、III(2-3分,38.6%)、IV(4-7分,21.3%)。
- 中位OS:MPSS I组91.0个月、II组69.8个月、III组45.0个月、IV组28.0个月(p < .001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Current standard predictive models of disease risk do not adequately account for the heterogeneity of survival outcomes in patients with new-diagnosed multiple myeloma (NDMM). In this retrospective, multicohort study, we collected clinical and genetic data from 1792 NDMM patients and identified the prognostic impact of all features. Using the top-ranked predictive features, a weighted Myeloma Prognostic Score System (MPSS) risk model was formulated and validated to predict overall survival (OS). In the training cohort, elevated lactate dehydrogenase level (LDH), International Staging System (ISS) Stage III, thrombocytopenia, and cumulative high-risk cytogenetic aberration (HRA) numbers were found to have independent prognostic significance. Each risk factor was defined as its weighted value respectively according to their hazard ratio for OS (thrombocytopenia 2, elevated LDH 1, ISS III 2, one HRA 1, and ≥2 HRA 2, points). Patients were further stratified into four risk groups: MPSS I (22.5%, 0 points), II (17.6%, 1 points), III (38.6%, 2-3 points), and IV (21.3%, 4-7 points). MPSS risk stratification showed optimal discrimination, as well as calibration, of four risk groups with median OS of 91.0, 69.8, 45.0, and 28.0 months, for patients in MPSS I to IV groups (p < .001), respectively. Importantly, the MPSS model retained its prognostic value in the internal validation cohort and an independent external validation cohort, and exhibited significant risk distribution compared with conventional prognostic models (R-ISS, R2-ISS, and MASS). Utilization of the MPSS model in clinical practice could improve risk estimation in NDMM patients, thus prompting individualized treatment strategies.
引用
- Mao X, Yan W, Mery D, et al. Development and validation of an individualized and weighted Myeloma Prognostic Score System (MPSS) in patients with newly diagnosed multiple myeloma. Am J Hematol. 2024. PMID: 38247315. doi:10.1002/ajh.27207
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。